Korea Investment Has Lowered Core Laboratories N V (CLB) Position; Petmed Express (PETS)’s Sentiment Is 1.38

January 14, 2018 - By Vivian Park

PetMed Express, Inc. and its subsidiaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States. The company has market cap of $1.08 billion. The firm markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats to retail customers. It has a 35.53 P/E ratio. It provides non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, thyroid, diabetes, pain medications, antibiotics, and other specialty medications, as well as generic substitutes.

Korea Investment Corp decreased Core Laboratories N V (CLB) stake by 15.49% reported in 2017Q3 SEC filing. Korea Investment Corp sold 8,300 shares as Core Laboratories N V (CLB)’s stock declined 4.78%. The Korea Investment Corp holds 45,300 shares with $4.47 million value, down from 53,600 last quarter. Core Laboratories N V now has $5.26B valuation. The stock increased 0.09% or $0.11 during the last trading session, reaching $119.1. About 318,286 shares traded. Core Laboratories N.V. (NYSE:CLB) has declined 5.82% since January 14, 2017 and is downtrending. It has underperformed by 22.52% the S&P500.

Analysts await PetMed Express, Inc. (NASDAQ:PETS) to report earnings on January, 22. They expect $0.36 earnings per share, up 50.00% or $0.12 from last year’s $0.24 per share. PETS’s profit will be $7.33 million for 36.76 P/E if the $0.36 EPS becomes a reality. After $0.43 actual earnings per share reported by PetMed Express, Inc. for the previous quarter, Wall Street now forecasts -16.28% negative EPS growth.

The stock increased 2.44% or $1.26 during the last trading session, reaching $52.94. About 675,148 shares traded or 3.47% up from the average. PetMed Express, Inc. (PETS) has risen 91.46% since January 14, 2017 and is uptrending. It has outperformed by 74.76% the S&P500.

Since January 1, 0001, it had 0 insider buys, and 3 insider sales for $1.05 million activity.

Oaktop Capital Management Ii L.P. holds 2.07% of its portfolio in PetMed Express, Inc. for 373,675 shares. Gratia Capital Llc owns 148,300 shares or 1.94% of their US portfolio. Moreover, Bogle Investment Management L P De has 0.82% invested in the company for 364,625 shares. The New York-based Lucus Advisors Llc has invested 0.49% in the stock. North Star Investment Management Corp., a Illinois-based fund reported 78,341 shares.

Korea Investment Corp increased D R Horton Inc (NYSE:DHI) stake by 10,500 shares to 960,088 valued at $38.34M in 2017Q3. It also upped Atmos Energy Corp (NYSE:ATO) stake by 12,400 shares and now owns 64,300 shares. Las Vegas Sands Corp (NYSE:LVS) was raised too.

Analysts await Core Laboratories N.V. (NYSE:CLB) to report earnings on January, 24. They expect $0.58 earnings per share, up 41.46% or $0.17 from last year’s $0.41 per share. CLB’s profit will be $25.61M for 51.34 P/E if the $0.58 EPS becomes a reality. After $0.48 actual earnings per share reported by Core Laboratories N.V. for the previous quarter, Wall Street now forecasts 20.83% EPS growth.

Investors sentiment decreased to 1.07 in 2017 Q3. Its down 0.01, from 1.08 in 2017Q2. It fall, as 45 investors sold CLB shares while 99 reduced holdings. 42 funds opened positions while 112 raised stakes. 49.25 million shares or 6.07% more from 46.43 million shares in 2017Q2 were reported. Jpmorgan Chase & has 0.02% invested in Core Laboratories N.V. (NYSE:CLB) for 935,695 shares. Snyder Capital Mgmt LP has 31,972 shares. Loring Wolcott And Coolidge Fiduciary Advisors Ltd Liability Partnership Ma invested in 34,236 shares. Baystate Wealth holds 20 shares. Nationwide Fund Advsrs accumulated 0.03% or 81,947 shares. Shelter Insur Retirement Plan accumulated 1.2% or 26,100 shares. Biondo Invest Advsr Limited Liability, Pennsylvania-based fund reported 38,427 shares. Connecticut-based Aqr Capital Mgmt Ltd Liability Corporation has invested 0.01% in Core Laboratories N.V. (NYSE:CLB). The Maryland-based Brown Advisory has invested 0.01% in Core Laboratories N.V. (NYSE:CLB). Sustainable Growth Advisers Lp stated it has 3.65% of its portfolio in Core Laboratories N.V. (NYSE:CLB). Sentinel Asset Management Incorporated has invested 0.09% in Core Laboratories N.V. (NYSE:CLB). Waddell And Reed Fincl reported 0.07% of its portfolio in Core Laboratories N.V. (NYSE:CLB). 34,486 were accumulated by Tiverton Asset Mngmt Lc. 19,489 were reported by Moors And Cabot. Texas-based Dimensional Fund Advsr Lp has invested 0.01% in Core Laboratories N.V. (NYSE:CLB).

Among 23 analysts covering Core Laboratories (NYSE:CLB), 12 have Buy rating, 0 Sell and 11 Hold. Therefore 52% are positive. Core Laboratories had 51 analyst reports since August 24, 2015 according to SRatingsIntel. RBC Capital Markets maintained the shares of CLB in report on Thursday, December 21 with “Buy” rating. The rating was initiated by DA Davidson with “Buy” on Thursday, October 6. The rating was initiated by Credit Suisse with “Neutral” on Thursday, September 1. The stock of Core Laboratories N.V. (NYSE:CLB) earned “Outperform” rating by RBC Capital Markets on Friday, September 18. The firm has “Buy” rating given on Wednesday, October 25 by ABN Amro. RBC Capital Markets maintained the shares of CLB in report on Thursday, January 28 with “Outperform” rating. Stephens initiated Core Laboratories N.V. (NYSE:CLB) rating on Tuesday, April 5. Stephens has “Equal-Weight” rating and $89 target. On Wednesday, July 26 the stock rating was maintained by Citigroup with “Neutral”. As per Monday, May 16, the company rating was maintained by Citigroup. Citigroup maintained it with “Neutral” rating and $115 target in Friday, March 18 report.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>